First Tracks Biotherapeutics, Inc. (TRAX) · Oct 15, 2026 · Share issuance
$110M minimum financing — At least $110M gross proceeds at $32.75 per share
First Tracks Biotherapeutics has signed a stock financing for at least $110 million after ANB033’s positive celiac data, extending development capital while adding dilution.
First Tracks is a newly independent, clinical-stage immunology biotech building its pipeline around ANB033 for celiac disease and eosinophilic esophagitis, with positive Phase 1b celiac Cohort 1 data announced on October 12, 2026 and additional clinical milestones ahead. This is a meaningful capital raise, not just paperwork. The company agreed to sell common stock at $32.75 per share, with closing proceeds required to be at least $110 million. 〔0〕 〔1〕 The supplied filing does not include Exhibit A’s investor-by-investor share totals, so the exact raise size and share count are not disclosed here; the minimum implies at least roughly 3.36 million new shares.
| Item | Filing terms |
|---|---|
| Minimum gross proceeds | $110.0 million (Conditions to the Obligation of the Company) |
| Purchase price | $32.75 per share (Definitions) |
| Minimum implied shares | ~3.36 million (calculated from filing terms) |
| Closing window | 2nd to 7th Business Day after October 15, 2026 (Closing) |
| Registration filing deadline | Within 30 days after closing (Registration Rights Agreement, Section 2(a)) |
| Registration-delay payment | 1.0% per 30 days, capped at 5.0% (Registration Rights Agreement, Section 2(d)) |
The financing strengthens execution capacity but brings real dilution. First Tracks had been operating with substantial launch capital and a development plan centered on ANB033’s next celiac cohort, expansion into additional inflammatory indications, and a later eosinophilic-esophagitis readout. The new cash should reduce near-term funding pressure and give management more room to advance that pipeline, but the benefit is purchased with a sizeable equity issuance relative to the roughly 35.7 million shares outstanding reported as of August 7, 2026—before accounting for any additional shares sold in this transaction. The timing also matters: the raise follows the positive ANB033 celiac readout, suggesting the company is financing into a strengthened clinical story rather than responding to a disclosed cash emergency.
The deal is signed, not yet closed. The agreement permits closing no earlier than the second Business Day and no later than the seventh Business Day after October 15, 2026. Investors also receive registration rights: First Tracks must file a resale registration statement within 30 days after closing and faces liquidated damages for missed deadlines, although payments are capped.
Bottom line: This materially improves First Tracks’ funding position as it moves from an encouraging early clinical result toward multiple 2027 milestones, but it is not an unambiguous win: the capital comes through meaningful equity dilution, and the financing remains subject to closing conditions. The business impact is therefore substantial and mixed rather than purely positive.
Financing closing, targeted October 19–27
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!